Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Junichi Nagakawa

Ieharu Hishinuma

Takashi Yamanaka

Shigeki Hibi

Kaname Miyamoto

Shinya Abe

Katsuya Tagami

Hiroyuki Yoshimura

Shuhei Miyazawa

Naoyuki Shimomura

Mitsuo Nagai

Takayuki Hida

Tsuneo Wakabayashi

Makoto Asada

Norimasa Miyamoto

Aichi Ogasawara

Kouichi Kikuchi

Kazuo Hirota

Seiko Higashi

Kenji Tai

Hitoshi Harada

Isao Yamatsu

Toshihiko Kaneko

Shigeru Souda

Norihiro Ueda

Seiichiro Nomoto

Masato Ueda

Makoto Okita

Nobuhisa Watanabe

Atsuhiko Kubota

Tsutomu Kawata

Hideaki Fujisaki

Junsaku Nagaoka

Toru Horie

Hidetoshi Kawashima

Naoko Nagaoka

Daisuke Iida

Yoshitake Ogata

Makoto Ikeda

Yasushi Okamoto

Tetsuya Kawahara

Masanobu Shinoda

Tsutomu Yoshimura

Yasunori Akita

Koichi Katayama

Yoshihiko Kotake

Osamu Asano

Hiromitsu Yokohama

Hiroki Terauchi

Tohru Horie

Koichi Kikuchi

Kiyoshi Oketani

Masahiro Yasuda

Makoto Nakagawa

Kotaro Kodama

A novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases is provided, which has an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by where Rand Rmay be the same or different and each represent a hydrogen atom or a C1-C6 alkyl group; Rrepresents (5,5-dimethyl-1,3-dioxan-2-yl)methoxy group, 5,7-dioxaspiro[2.5]oct-6-ylmethoxy group, 1,5,9-trioxaspiro[5.5]undec-3-ylmethoxy group, or (2,2-dimethyl-1,3-dioxan-5-yl)methoxy group; R, R, Rand Rrepresent a hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 haloalkyl group, C1-C6 alkoxy group or C1-C6 haloalkoxy group; and Wrepresents a single bond, methylene or ethylene group, a salt thereof or a solvate of these.

Benzimidazole compound

A compound represented by the following general formula (1), or a salt or hydrate thereof: [Formula 1] wherein Rrepresents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, Rrepresents a hydrogen atom or a C1-C6 alkyl group, Rrepresents methyl or ethyl group, Rrepresents a C1-C6 alkyl group, Rrepresents a hydrogen atom, provided that a compound wherein Ris a C1-C6 alkyl group unsubstituted or substituted with a halogen atom and Ris a hydrogen atom is excluded.

Imidazopyridine compound

An object of the present invention is to provide a novel chemical compound useful as a therapeutic or prophylactic agent for acid-related diseases, having an excellent inhibitory effect against gastric acid secretion, an excellent effect of maintaining the inhibitory effect against gastric acid secretion, thereby maintaining intragastric pH high for a long time, and having more safety and appropriate physicochemical stability. Provided is a compound represented by 

A compound having excellent adenosine receptor (A, A, Areceptor) antagonistic action, of the following formula, a salt thereof or a solvate of them: wherein, Rand R, same or different, each represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, an aromatic hydrocarbon cyclic group, an acyl group or an alkylsulfonyl group, which groups may be substituted (except the hydrogen atom); Rrepresents a hydrogen atom, a halogen atom, a cyano group, an alkyl group, an alkenyl group, an alkynyl group, an aromatic hydrocarbon cyclic group, a nitrogen atom, an oxygen atom or a sulfur atom, which groups may be substituted (except the hydrogen atom, the halogen atom and the cyano group); Rrepresents an aromatic hydrocarbon cyclic group which may be substituted, and Rrepresents an aromatic hydrocarbon cyclic group which may be substituted.

Pyrimidine compound and medicinal composition thereof

Mono- or polyenic carboxylic acid derivatives

To provide novel compounds relating to retinoid which can substitute for retinoic acid used for preventing and treating several diseases and having antagonism against retinoid. Heterocyclic compounds represented by the general formula (1-I) or physiologically acceptable salts thereof:

Compounds of the formula and compounds of the formula ##STR1## or their salts have the potent ability to bind to retinoic acid receptors thus useful in treating psoriasis and rheumatoid arthritis.

Mono-or polyenic carboxylic acid derivatives

Heterocycle-containing carbonic acid derivatives

A new benzodioxole derivative has a substituent in the phenyl ring which is a carboxyalkylthioalkyl or the like and is effective to treat a liver disease.

Benzodioxole derivatives

A quinone derivative useful in the treatment of hepatic diseases defined by the general formula: ##STR1## where X and Y may be the same or different from each other and are each a hydroxyl group, a group represented by the formula --(--OCH.sub.2 --).sub.n --OR.sup.6, wherein n is 0 or 1 and R.sup.6 is a lower alkyl group, or an acyl group.

Quinone derivatives and pharmacological use

A quinone derivative useful in the treatment of hepatic diseases defined by the general formula: ##STR1## where R1 is selected from the group consisting of alkyl, alkenly, alkynyl or heterocycle, R2 is a substituted nitrogen containing radical wherein the substituents on said nitrogen are selected from the group consisting of hydrogen, substituted or unsubstituted lower alkyl or heterocycles, and where said nitrogen may be a ring heteroatom, and R3, R4 and R5, may be the same or different and each are hydrogen, lower alkyl or lower alkoxy groups.

Ouinone derivatives and pharmacological use

Benzodioxale derivatives

Growing community of inventors

Ibaraki, Japan

Junichi Nagakawa